Abstract
Genome-wide association studies (GWAS) have significantly advanced the understanding of genetic mechanisms underlying complex human diseases and traits by systematically identifying genetic variants linked to diverse phenotype traits across diverse populations. Large-scale analyses that combine multiple phenotypes are especially valuable, as they can reveal shared genetic architectures and patterns of comorbidity, refining disease classification and risk prediction. Here, we conducted comprehensive GWAS analyses based on Estonian Biobank EHR data, focusing on 4,884 ICD-10-based disease phenotypes, in a cohort of 206,159 Estonian Biobank participants. By analysing their genotype data, altogether 18,977,777 SNV and indel variants (including common, low-frequency and rare variants), our analyses revealed 2,127 unique genome-wide significant loci, including 778 putatively novel locus-phenotype associations. Further investigation into coding variants revealed 835 significant associations, including well-established ACMG pathogenic variants and multiple putatively novel associations. Notably, a missense variant in SCN11A, which encodes the Nav1.9 sodium channel involved in pain signalling, was associated with decreased migraine risk, while an Estonian-enriched GOT1 variant considerably affected aspartate transaminase enzymatic function. Our study highlights the potential of population-based biobanks in discovering both common and rare genetic associations, contributing to the identification of novel disease associated loci and expanding the catalog of human disease related genetic variants.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by the European Union through Horizon 2020 and Horizon Europe research and innovation program under grants no. 874627 (EXPANSE) (JK); 894987 (GENOMEPEP) (EA); 101153901 (CHRONOPIA) (TP); 101096888 (DISCERN) (JK); 101137201 (CLARITY) (EA, KB, LT); 101057721 (PROPHET) (AR); 101128023 (JAPreventNCD) (AR); 101080009 (CAN.HEAL) (AR); 101137154 (WISDOM) (EA); 101137278 (CVDLINK) (UV); and Estonian Research Council Grants PRG555 (Evaluation of genetic variants potentially linked to actionable health risks) (AR); and PRG1291 (Systematic phenome-wide search for genetic modulators in health and disease) (AA, EA, KB, JK, UV, PP).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The activities of the Estonian Biobank are regulated by the Human Genes Research Act, which was adopted in 2000 specifically for the operations of Estonian Biobank. Individual level data analysis in Estonian Biobank was carried out under ethical approval 1.1-12/624 from the Estonian Committee on Bioethics and Human Research (Estonian Ministry of Social Affairs), using data according to release application 3-10/GI/31689 from the Estonian Biobank.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos